drugset / Trial / NCT01361191

Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

NCT01361191

Phase 2 Completed 71 enrolled Spanish Lymphoma Cooperative Group
NaSingle-groupOpen-labelTreatment

Summary

The aim of the study is to evaluate the event free survival at three years in patients with diffuse large B-cell lymphoma with poor prognostic factors receiving R-MegaCHOP as induction therapy. Patients with positive PET after three cycles of R-MegaCHOP receive early salvage treatment with R-IFE and autologous stem cell transplantation. Patients with negative PET after three cycles of R-MegaCHOP are treated with three additional cycles of R-MegaCHOP without transplant.

Timeline

Start
2007-06
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CYCLOPHOSPHAMIDE ANHYDROUS Small molecule 1500 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 65 mg/m2 Intravenous
Subject Etoposide Small molecule 900 mg/m2 Intravenous
Subject Ifosfamide Small molecule 10 g Intravenous
Subject Prednisone Other / unclassified 60 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous